Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
173 working days (255)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
Renal Cell Carcinoma
KEYTRUDA® (concentrated injection; powder for injection) in combination with axitinib, is now also indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).